ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $4.60.

A number of research firms recently weighed in on ALXO. Weiss Ratings reiterated a “sell (d-)” rating on shares of ALX Oncology in a research report on Friday, June 26th. Wall Street Zen upgraded ALX Oncology from a “sell” rating to a “hold” rating in a report on Saturday, May 9th.

ALX Oncology Stock Performance

ALXO opened at $1.92 on Tuesday. The firm has a market cap of $258.36 million, a PE ratio of -1.29 and a beta of 0.42. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $1.88 and a 200-day simple moving average of $1.86. ALX Oncology has a fifty-two week low of $0.44 and a fifty-two week high of $2.66.

ALX Oncology (NASDAQ:ALXO) last issued its earnings results on Friday, May 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). As a group, equities analysts predict that ALX Oncology will post -0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Bridgeway Capital Management LLC purchased a new stake in shares of ALX Oncology in the 3rd quarter valued at approximately $66,000. Invesco Ltd. acquired a new position in ALX Oncology in the 1st quarter worth approximately $46,000. OMERS ADMINISTRATION Corp purchased a new position in ALX Oncology during the 1st quarter worth approximately $150,000. Seven Fleet Capital Management LP purchased a new position in ALX Oncology during the 4th quarter worth approximately $133,000. Finally, AQR Capital Management LLC grew its position in ALX Oncology by 183.6% during the 1st quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock worth $74,000 after purchasing an additional 77,065 shares in the last quarter. 97.97% of the stock is owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.